C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 114 filers reported holding C4 THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $81,427 | -22.3% | 25,932 | +45.9% | 0.00% | – |
| Q4 2022 | $104,843 | -31.5% | 17,770 | +1.6% | 0.00% | – |
| Q3 2022 | $153,000 | +10.1% | 17,489 | -5.1% | 0.00% | – |
| Q2 2022 | $139,000 | -78.7% | 18,428 | -31.7% | 0.00% | – |
| Q1 2022 | $654,000 | -63.8% | 26,990 | -51.8% | 0.00% | -100.0% |
| Q4 2021 | $1,805,000 | +67.1% | 56,040 | +131.7% | 0.00% | 0.0% |
| Q3 2021 | $1,080,000 | +30.4% | 24,186 | +10.6% | 0.00% | – |
| Q2 2021 | $828,000 | +210.1% | 21,859 | +203.0% | 0.00% | – |
| Q1 2021 | $267,000 | +2.7% | 7,214 | -8.2% | 0.00% | – |
| Q4 2020 | $260,000 | – | 7,862 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $17,795,000 | 7.09% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $60,745,000 | 3.44% |
| Soleus Capital Management, L.P. | 464,068 | $17,166,000 | 3.09% |
| Cormorant Asset Management, LP | 2,490,065 | $92,107,000 | 2.05% |
| P.A.W. CAPITAL CORP | 50,000 | $1,850,000 | 1.63% |
| Perceptive Advisors | 3,158,566 | $116,835,000 | 1.48% |
| SPHERA FUNDS MANAGEMENT LTD. | 497,136 | $18,389,000 | 1.41% |
| Mizuho Securities Co. Ltd. | 169,392 | $6,266,000 | 1.30% |
| RTW INVESTMENTS, LP | 2,149,228 | $79,437,000 | 1.24% |
| Darwin Global Management, Ltd. | 140,034 | $5,180,000 | 1.01% |